Chlamydia Infection Diagnostic and Therapeutic Market - Global Segments and Forecasts up to 202317 Dec 2015
Chlamydia is a common sexually transmitted infection caused by bacterium Chlamydia trachomatis. Chlamydia is among the most prevalent sexually transmitted disease (STDs) and according to Centers for Disease Control and Prevention (CDC), it comprises of largest proportion of all STDs reported in the United States since 1994. In 2012, a total of 1.4 million cases of Chlamydia infection were reported to CDC in 50 states and the District of Columbia. Overall the case rate among males in 2012 rose by 3.2% during 2011-2012 which is approximately half the case rate reported in females. Chlamydia infection among women is generally asymptomatic. However the disease if left untreated can develop into pelvic inflammatory disease (PID) which is a major cause of infertility, ectopic pregnancy, and chronic pelvic pain. Similar to other STDs, chlamydia infection might facilitate the transmission of human immunodeficiency virus (HIV) infection.
Browse Full Report Details:- http://www.transparencymarketresearch.com/chlamydia-infection-diagnostic-therapeutic-market.html
Moreover, pregnant women infected with chlamydia can pass the infection to their infants during delivery, potentially resulting in neonatal ophthalmia and pneumonia. In Europe there are more than 250,000 new cases are reported each year and women below 24 years in Europe have highest number of infection. In 2012, National Health Service, U.K., 206,912 people were tested positive for Chlamydia in England of which 64% were below 25 years of age.
Among women, symptoms of chlamydia include abnormal vaginal discharge, painful periods and abdominal pain with fever. Additionally itching and burning around vagina and mild pain during urination. Whereas among men symptom such as cloudy discharge, painful urination, burning around genital area and swelling of testicles are commonly found. Commonly used drugs for treating chlamydia include Amoxil, Doryx, Doxycycline, Erythrocin, Floxin, Gantrisin, Trimox, Zithromax and others. Some of the emerging diagnostic techniques in global Chlamydia Infection Diagnostic and Therapeutic market comprise molecular diagnostic, immunoassays, monoclonal antibodies, flow cytometry and gel moicrodroplet based testing. Major drivers for the growth of the market include increasing collaboration agreement with distributors, manufacturers and universities pertaining to manufacturing and research activities have escalated the market in past few years. Pipelined drugs in the market include CEL-1000, Cyanovirin-N, GEN-001, acALY18 and others.
Geographically the market for chlamydia is predominated by developed regions such as the United States and Europe. Major contributors to the growth of these markets include intense research funding and government interventions for developing cheap and affordable medications for sexually transmitted diseases under Affordable CARE Act. Availability of advanced diagnostic centers, clinics and hospitals has also contributed towards the growth and development of market in past one decade. Asia Pacific and Rest of the World market is potentially a lucrative market and has fastest growth rate as compared to other regions pertaining to increasing sexually transmitted diseases incidences and lack of appropriate diagnostic and care centers for sexually transmitted infection/ diseases especially in the under developed parts of Asia-Pacific and Rest of the World is restraining the growth of the market. Approximately 43 million new cases of chlamydia are reported in Southeast Asian region. Whereas according to the 1999 World Health Organization report prevalence rate of chlamydia in Western Pacific region ranges from 5.7% in Thailand up to 17% in India. The aforementioned data clearly depicts the latent growth potential for drug and diagnostic companies manufacturing chlamydia related products.
Some of the key players operating in global chlamydia infection diagnostic and therapeutic market include: Abbott Laboratories, Danaher Corporation, bioMerieux, DiaSorin SpA, NANOGEN Biopharmaceutical, Siemens AG, Thermo Fisher Scientific, Novartis Diagnostics, Fujirebio Diagnostics, Inc. and others.
Enquiry For Buying This Report:- http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=8212